Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 76 of 151

  1. KT621-AS-202

    Kymera Therapeutics

    Uncontrolled Moderate to Severe Eosinophilic Asthma

    phase 2 small molecule active

    1 trial

  2. KTE-C19-102

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  3. KVD001 Injection

    Kalvista Pharmaceuticals (Ireland) Limited

    Diabetic Macular Edema

    phase 2 small molecule completed

    2 trials

  4. KVD824

    Kalvista Pharmaceuticals (Ireland) Limited

    Angioedema, Hereditary, Types I and II

    phase 2 small molecule terminated

    1 trial

  5. KVD900

    Kalvista Pharmaceuticals (Ireland) Limited

    Hereditary Angioedema

    phase 2 small molecule completed

    2 trials

  6. KW-2478

    KYOWA KIRIN AUSTRALIA PTY LTD

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  7. KYV-101

    Kyverna Therapeutics

    Multiple Sclerosis, Primary Progressive

    phase 2 mab active

    1 trial

  8. KYV-101

    Kyverna Therapeutics

    Systemic Sclerosis

    phase 2 mab active

    1 trial

  9. KYV-101 anti-CD19 CAR-T cell therapy

    Kyverna Therapeutics

    Lupus Nephritis

    phase 2 mab active

    2 trials

  10. KYV101

    Kyverna Therapeutics

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  11. KYV101-003

    Kyverna Therapeutics

    Lupus Nephritis

    phase 2 other active

    1 trial

  12. KYV101-007

    Kyverna Therapeutics

    Primary or Secondary Progressive Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  13. Kanglaite

    The First People's Hospital of Lianyungang

    Head and Neck Cancer

    phase 2 small molecule completed

    1 trial

  14. Kapruvia 50 micrograms/mL solution for injection

    Fresenius Kabi Australia Pty Limited

    Pruritus, Chronic Kidney Diseases

    phase 2 small molecule active

    1 trial

  15. Karelizumab combined with etoposide and cisplatin

    Jian Li

    Carcinoma

    phase 2 small molecule active

    1 trial

  16. Ketamine

    Grace Therapeutics

    Obstetric Pain

    phase 2 small molecule completed

    1 trial

  17. Ketamine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule terminated

    1 trial

  18. Ketamine Hydrochloride

    BRIGHT MINDS BIOSCIENCES INC.

    Depression

    phase 2 small molecule completed

    1 trial

  19. L-Glutamine

    BRIGHT MINDS BIOSCIENCES INC.

    Pulmonary Hypertension

    phase 2 small molecule completed

    1 trial

  20. L-citrulline

    United Therapeutics Europe Ltd

    Post Deployment Related Asthma

    phase 2 small molecule active

    1 trial

  21. L2023-K003-002

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  22. LAAM

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 2 small molecule completed

    1 trial

  23. LAAM

    BRIGHT MINDS BIOSCIENCES INC.

    Behavior Therapy

    phase 2 other completed

    1 trial

  24. LAB4

    Cardiff Oncology

    Graves' Disease

    phase 2 mab active

    1 trial

  25. LAD328, SODIUM CHLORIDE

    Almirall, S.A.

    moderate-to-severe hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

  26. LB-100

    LIXTE BIOTECHNOLOGY HOLDINGS, INC.

    Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  27. LB-102

    LB PHARMACEUTICALS INC

    Bipolar I Disorder

    phase 2 small molecule active

    1 trial

  28. LB-208, LB-208

    AOP Orphan Pharmaceuticals GmbH

    Relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)

    phase 2 small molecule active

    1 trial

  29. LB101

    Centessa Pharmaceuticals plc

    Advanced Solid Tumor

    phase 2 small molecule terminated

    1 trial

  30. LB101-101

    Centessa Pharmaceuticals plc

    Advanced solid tumors

    phase 2 other active

    1 trial

  31. LB1410

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solid Tumor

    phase 2 small molecule active

    1 trial

  32. LB54640

    Rhythm Pharmaceuticals Netherlands B.V.

    Hypothalamic Obesity

    phase 2 small molecule completed

    1 trial

  33. LBH581

    BRIGHT MINDS BIOSCIENCES INC.

    Small Cell Lung Carcinoma

    phase 2 small molecule completed

    1 trial

  34. LBL-007

    BEONE MEDICINES AUS PTY LTD

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  35. LBL-024 for Injection

    The First People's Hospital of Lianyungang

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  36. LBR-101 High Dose

    Teva Pharma GmbH

    Episodic Migraine Headache

    phase 2 small molecule completed

    1 trial

  37. LBR-101 High Dose

    Teva Pharma GmbH

    Chronic Migraine

    phase 2 small molecule completed

    1 trial

  38. LCAR-B38M CAR-T Cell

    Nanjing Legend Biotech Co.

    Multiple Myeloma

    phase 2 mab terminated

    1 trial

  39. LCAR-B38M CAR-T cell injection

    Nanjing Legend Biotech Co.

    Refractory or Relapsed Multiple Myeloma

    phase 2 mab active

    1 trial

  40. LCZ696

    Novartis Pharmaceuticals

    Hypertension

    phase 2 small molecule completed

    2 trials

  41. LDE225 0.75%

    Novartis Pharmaceuticals

    Sporadic Superficial and Nodular Skin Basal Cell Carcinomas

    phase 2 small molecule terminated

    1 trial

  42. LE 7X01

    Pharming Technologies B.V.

    primary immunodeficiency

    phase 2 small molecule active

    1 trial

  43. LE 8201

    Pharming Technologies B.V.

    Common variable immunodeficiency

    phase 2 small molecule active

    1 trial

  44. LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy

    The George Institute

    Colon cancer

    phase 2 other active

    1 trial

  45. LEN+SIN+DEB-TACE+HAIC

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma Non-resectable

    phase 2 other active

    1 trial

  46. LENVIMA 4 mg hard capsules

    Pari Pharma GmbH

    Patients with Biopsy-proven or radiologically-suggested BCLC A HCC eligible for PA and comprising at least one of the following criteria: - Single tumour>3 cm≤ 5cm or - multiple tumours (max 3 lesions ≤ 3cm) or - Single tumour between 2 and 3 cm with at least one of the following characteristic: • Serum AFP>100 ng/mL • Infiltrative form • Macro-trabecular subtype (if applicable)

    phase 2 small molecule active

    1 trial

  47. LENVIMA 4 mg hard capsules

    Pari Pharma GmbH

    Non-resectable hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  48. LEO 90105

    LEO Pharma A/S

    Psoriasis Vulgaris

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.